Minsig Choi is an Oncology physician affiliated with Stony Brook University. OpenAlex indexes 30 publications with 394 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Medical Village Dr
Edgewood, KY 410173403
Telephone
859-301-4000Provider last certified this registry record 18 Oct 2022.
Clinical trials
- Phase I Trial HIPEC With Nal-irinotecan
Sponsor: Stony Brook University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202510 payments$18,659openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year20257 payments$10,921openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
42.3%Phenothiazine27.3%Prochlorperazine Maleate100%Part D≥60 patientsOpioid Agonist15%Oxycodone Hcl57%Oxycodone-Acetaminophen43%Part D≥20 patientsSensory organs
18.7%Corticosteroid18.7%Dexamethasone100%Part D≥47 patientsMetabolism & gastrointestinal
15.5%Antidiarrheal microorganisms4.9%Creon100%Part D<11 patientsProton pump inhibitor4.2%Pantoprazole Sodium100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Keratin 17 as a Predictor of Chemotherapy Response in Pancreatic Ductal Adenocarcinoma
SSRN Electronic Journal
2023 - Perioperative chemotherapy versus adjuvant chemotherapy strategies in resectable gastric and gastroesophageal cancer: A Markov decision analysis
European Journal of Surgical Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Ramin Parsey, MD, PhD
Stony Brook University
Basil Rigas, MD
Stony Brook University
Bettina Fries, MD
Stony Brook University
Nancy Epstein, MD
Stony Brook University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”